Business Wire

CA-TALKDESK-INC

Share
German Solar Company Zolar Chooses Talkdesk to Power Contact Center Solution

Talkdesk®, Inc. , the global customer experience leader for customer-obsessed companies, has been selected by Zolar , a Berlin-based green tech company, as its contact center provider. Talkdesk will supply voice services and Talkdesk for Salesforce™ to the Zolar team of solar energy advisers, enabling them to provide more streamlined interactions with customers while leveraging and maintaining a comprehensive view of the customer journey.

Zolar is the brainchild of founder Alex Melzer, who gained inspiration for starting the company after embarking on a 2,600km bicycle ride across South America in 2015. Moved by the scenes of man-made climate change, which he observed along the way, Melzer became determined to make a difference. He set up Zolar the following year with a mission to create a future powered by clean energy. The company now offers a range of products for customers to generate affordable and environmentally friendly electricity.

Zolar employs a team of solar experts who advise customers throughout all phases of the purchasing process, from initial inquiry to the creation of a rooftop solar energy solution tailored to the unique needs of each customer. With Talkdesk CX Cloud™ , an end-to-end customer experience solution, Zolar can quickly and easily field their typical daily volume of more than 1,000 customer calls, even when staff work from home. Through the solution’s deep integration with Salesforce, they can also access and maintain a complete view of each customer engagement to further personalize the experiences.

“We needed a solution with advanced routing capabilities and a view into call behaviour,” said Markus Schaffrinski, Chief Technology Officer, Zolar. “Talkdesk CX Cloud gives us a sophisticated, yet simple-to-use tool with smart routing right out of the box. By allowing us to respond more efficiently, from anywhere, and provide a better overall experience, our customers can come away not only feeling good about choosing a clean energy solution, they also feel added confidence in having entrusted Zolar to power it.”

“The fast growth of Zolar is rooted in its passion for the environment and focus on delivering the highest quality product and service. They exemplify the magic that happens when purpose truly drives execution,” said Tiago Paiva, chief executive officer and founder, Talkdesk. “As more households throughout Europe turn to green energy, Talkdesk looks forward to supporting their mission with advanced contact center tools for helping Zolar deliver more great customer experiences.”

Additional Resources

Social Networks

About Talkdesk

Talkdesk® is a global customer experience leader for customer-obsessed companies. Our contact center solution provides a better way for businesses and customers to engage with one another. Our speed of innovation and global footprint reflect our commitment to ensure businesses everywhere can deliver better customer experiences through any channel, resulting in higher customer satisfaction, cost savings and profitability. Talkdesk CX CloudTM is an end-to-end customer experience solution that combines enterprise scale with consumer simplicity. Over 1,800 innovative companies around the world, including IBM, Acxiom, Trivago, and Fujitsu partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com .

About Zolar

The greentech company Zolar offers photovoltaic systems, which homeowners are able to custom plan, compare and order online, at a fixed price. By means of the Zolar online configurator, homeowners are able to customize the components of their solar energy system according to their needs and will receive a personal consultation at the same time from one of our solar energy experts. Zolar has a broad network of local partner companies that install the systems on-site. The Berlin-based start-up employs 190 people and pursues the vision of installing a solar system on every roof worldwide to enable the independence of private households from the public power grid. Zolar empowers its customers to promote the energy turnaround, to reduce the CO2 footprint and thus make an effective contribution to climate protection. www.zolar.de

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks ™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye